dc.contributor.author | Castleton, A | en_US |
dc.contributor.author | Dey, A | en_US |
dc.contributor.author | Beaton, B | en_US |
dc.contributor.author | Patel, B | en_US |
dc.contributor.author | Aucher, A | en_US |
dc.contributor.author | Davis, DM | en_US |
dc.contributor.author | Fielding, AK | en_US |
dc.date.accessioned | 2024-01-04T14:50:15Z | |
dc.date.issued | 2014-02-27 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/93387 | |
dc.description.abstract | Clinical trials of oncolytic attenuated measles virus (MV) are ongoing, but successful systemic delivery in immune individuals remains a major challenge. We demonstrated high-titer anti-MV antibody in 16 adults with acute lymphoblastic leukemia (ALL) following treatments including numerous immunosuppressive drugs. To resolve this challenge, human bone marrow-derived mesenchymal stromal cells (BM-MSCs) were used to efficiently deliver MV in a systemic xenograft model of precursor B-lineage-ALL. BM-MSCs were successfully loaded with MV ex vivo, and MV was amplified intracellularly, without toxicity. Live cell confocal imaging demonstrated a viral hand-off between BM-MSCs and ALL targets in the presence of antibody. In a murine model of disseminated ALL, successful MV treatment (judged by bioluminescence quantification and survival) was completely abrogated by passive immunization with high-titer human anti-MV antibody. Importantly, no such abrogation was seen in immunized mice receiving MV delivered by BM-MSCs. These data support the use of BM-MSCs as cellular carriers for MV in patients with ALL. | en_US |
dc.format.extent | 1327 - 1335 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Blood | en_US |
dc.subject | Adult | en_US |
dc.subject | Animals | en_US |
dc.subject | Cells, Cultured | en_US |
dc.subject | Chlorocebus aethiops | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunity, Humoral | en_US |
dc.subject | Measles virus | en_US |
dc.subject | Mesenchymal Stem Cell Transplantation | en_US |
dc.subject | Mesenchymal Stem Cells | en_US |
dc.subject | Mice | en_US |
dc.subject | Mice, Inbred C57BL | en_US |
dc.subject | Mice, SCID | en_US |
dc.subject | Oncolytic Virotherapy | en_US |
dc.subject | Oncolytic Viruses | en_US |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | en_US |
dc.subject | Vero Cells | en_US |
dc.subject | Xenograft Model Antitumor Assays | en_US |
dc.title | Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1182/blood-2013-09-528851 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/24345754 | en_US |
pubs.issue | 9 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 123 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |